Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies (Q33393525)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies |
scientific article |
Statements
1 reference
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies (English)
1 reference
Monica Mita
1 reference
Kevin R Kelly
1 reference
Alain Mita
1 reference
Alejandro D Ricart
1 reference
Ofelia Romero
1 reference
Anthony Tolcher
1 reference
Laurel Hook
1 reference
Chukwuemeka Okereke
1 reference
Ilya Krivelevich
1 reference
Daniel P Rossignol
1 reference
Francis J Giles
1 reference
Eric K Rowinsky
1 reference
Chris Takimoto
1 reference
1 January 2011
1 reference
1 reference
17
1 reference
193-200
1 reference
Identifiers
1 reference
1 reference